PRESS RELEASE
News
-
-
-
PRESS RELEASE
Spectral Capital (FCCN) Announces $15 Million Private Placement Memorandum Agreement with Spark Market
Spectral Capital Corporation partners with Spark Market to raise $15 million for Quantum Bridge Program & Green Micro Data Center Network expansion, promoting accessibility to high-impact investments and sustainability -
-
PRESS RELEASE
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications -
PRESS RELEASE
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS -
REGULATED PRESS RELEASE
i2S : Rapport Financier Semestriel 2024 - Annule et remplace
-
-
PRESS RELEASE
Research Dynamics - Report on CPHN: Investor Day Update
CPH Group outlines strategic objectives focusing on innovation, growth in niche markets, and operational excellence, particularly in the Packaging Division. Special focus on pharmaceutical packaging market and long-term growth opportunities -
